You are currently accessing this Site as a guest. Please login or register by clicking Here
Click here to see who are advancing transfusion alternatives and blood management.
Click here and see who are advancing transfusion alternatives and blood management.

Go Back   NoBlood > Resources > Medical Articles and Abstracts


Welcome to NoBlood.

You are currently accessing this Site as a guest which gives you limited access to most discussions and other features. By registering you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, register today!

If you have any problems with the registration process or your account login, please contact contact us. If you forgot your password, click here to request a new one.

Tags: , , ,

Reply
 
LinkBack Thread Tools Rate Thread Display Modes
  #1 (permalink)  
Old 05-16-2006, 03:11 AM
Registered User
 
Join Date: Jan 2003
Posts: 1,438
Thanks: 7
Thanked 115 Times in 67 Posts
Jan B. Wade is on a distinguished road
Erythropoietin is an effective clinical modality for reducing RBC transfusion

http://www.ncbi.nlm.nih.gov/entrez/q...=pubmed_docsum


Can J Anaesth. 2005 Apr;52(4):362-8.







Erythropoietin is an effective clinical modality for reducing RBC transfusion in joint surgery.

Karkouti K, McCluskey SA, Evans L, Mahomed N, Ghannam M, Davey R.

Department of Anesthesia, Unversity Health Network, University of Toronto, Ontario, Canada. keyvan.karkouti@uhn.on.ca

PURPOSE: Efficacy trials of preoperative erythropoietin therapy (PET) recommend a dosing schedule that cannot always be adhered to in everyday clinical practice. Consequently, we instituted a flexible dosing schedule and routinely offered it to anemic patients [hemoglobin (Hb)] < or = 130 g x L(-1)) undergoing total joint arthroplasty (TJA). The purpose of this observational, cohort study was to assess the effectiveness of this practice in reducing red blood cell (RBC) transfusion. METHODS: After obtaining Institutional Ethics Board approval, data were collected prospectively on all patients who underwent TJA at our institution from July 1999 to June 2003. Patients with baseline Hb < or = 130 g x L(-1) were offered PET as follows: one to three sc injections (20,000 IU for those < or = 70 kg, and 40,000 IU for those > 70 kg) every three to seven days before surgery. Since treatment was not randomly assigned, multivariable logistic regression analysis and propensity score case-control matching were used to adjust for baseline differences in patient demographics and perioperative risk factors for RBC transfusion. The adjusted relationship between PET and RBC transfusion was then determined. RESULTS: Of the 1,782 patients that underwent TJA during the study period, 770 (47.9%) had a Hb < 130 g x L(-1). Of these patients, 214 received PET and their RBC transfusion rate was 16.4%, whereas the transfusion rate was 56.1% in those who did not receive PET (P < 0.0001). The adjusted odds ratio of RBC transfusion with PET was 0.33 (95% confidence interval = 0.21-0.49). CONCLUSION: PET, used as part of routine clinical practice, is an effective blood conservation modality.
__________________
Mr. Jan B. Wade
Blood Management Consultant
Enhance Outcomes - Control Cost
For Information Call - 360 296-1807
Email

Digg this Post!Add Post to del.icio.usBookmark Post in TechnoratiFurl this Post!
Reply With Quote
Reply

  NoBlood > Resources > Medical Articles and Abstracts



Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools
Display Modes Rate This Thread
Rate This Thread:

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is On
Trackbacks are On
Pingbacks are On
Refbacks are On

Similar Threads
Thread Thread Starter Forum Replies Last Post
Erythropoietin in pediatric cardiac surgery: clinical efficacy and effective dose Sharon Grant Medical Conditions and Treatments 0 11-11-2005 10:42 PM
Cost-effectiveness of recombinant human erythropoietin for reducing RBC Transfusion Jan B. Wade Medical Articles and Abstracts 0 06-13-2005 04:52 AM
Erythropoietin is an effective clinical modality for reducing RBC transfusion in join Nika Medical Articles and Abstracts 0 04-13-2005 08:04 PM
Clinical characteristics of erythropoietin-associated pure red cell aplasia Nika Medical Articles and Abstracts 0 04-01-2005 04:55 PM
Recombinant erythropoietin in clinical practice Nika Medical Articles and Abstracts 4 03-21-2005 09:43 AM


All times are GMT -7. The time now is 05:55 PM.






Featured
Hospital Sponsors
Hospitals Directory

Click here to help us make a difference today. Yes, for the price of a cup of coffee, you can help NoBlood continue its mission to advance knowledge and awareness of transfusion alternatives, blood conservation, blood management, bloodless medicine and bloodless surgery.
Please help us continue to make a difference today.

Highlights
Looking for help?
Can you help?

Key Wiki Articles
Register - FAQ - Members List - Calendar - Files - Videos - Mark Forums Read - NoBlood.org RSS Feeds

Powered by vBulletin® Version 3.6.10
Copyright ©2000 - 2008, Jelsoft Enterprises Ltd.
SEO by vBSEO 3.1.0
Copyright © 1996 - 2008, Bloodless Healthcare International, Inc.